Breast Cancer

, Volume 5, Issue 3, pp 211–217

Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy

  • Ruth M. O’Regan
  • Gale M. England
  • Jennifer I. MacGregor
  • Kathy A. Yao
  • Henry D. Muenzner
  • Hiroyuki Takei
  • V. Craig Jordan
Review Article

Summary and Conclusions

Laboratory models for breast and endometrial cancer have had an enormous impact on the clinical development of antiestrogens. Results from the DMBA-induced rat mammary cancer model has provided the scientific principles required to evaluate long-term adjuvant tamoxifen therapy. Similarly, the athymic mouse model allowed the identification of clinically relevant mechanisms of drug resistance to tamoxifen and a model system to test new agents for cross resistance. Additionally, the endometrial cancer model has allowed the identification of agents that cause a slight increase in the risk of endometrial cancer long before the data would have be available from clinical studies. However, it should be stressed that this model is really only relevant for agents to be tested as preventives in normal women. The risks of developing endometrial cancer during tamoxifen therapy are slight compared with the survival benefit in controlling breast cancer.

Finally the discovery of the carcinogenic potential of tamoxifen in the rat liver, 20 years after it was first introduced into clinical practice, raises an interesting issue. If the studies of liver carcinogenicity had been completed and published in the early 1970’s there would be no tamoxifen and tens of thousands of women with breast cancer would have died prematurely. In fact there would have been no incentive to develop new agents as alternatives to tamoxifen or following tamoxifen failure. Most importantly, we would not have any knowledge about the target-site or selective actions of antiestrogens. All the current interest in selective estrogen receptor modulators (SERMs) is based on the huge clinical data base obtained by studying tamoxifen. The success of tamoxifen as an agent that preserves bone density, lowers cholesterol and prevents contralateral breast cancer43 has become a classic example of a multimechanistic drug. These concepts have acted as a catalyst to develop new agents for new applications. The laboratory studies of raloxifene44-46) provided the scientific rationale for the use of raloxifene as a preventive for osteoporosis47) but with the goal of preventing breast cancer in post-menopausal women48,49) (Fig 5). It is clear that the close collaboration between laboratory and clinical research has revolutionized the prospects for women’s health care in the 21st century.

Key words

Tamoxifen Toremifene Raloxifene Endometrial cancer 

Abbreviations

IARC

International Agency for Research on Cancer

ER

Estrogen receptor

DMBA

Dimethylbenzanthracene

SERM

Selective estrogen receptor modulator

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Lancet 339:1–15, 71-85, 1992.Google Scholar
  2. 2).
    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen.Pharmacol Ther 25:127–205, 1984.PubMedCrossRefGoogle Scholar
  3. 3).
    Rose C, Thorpe SM, Andersen KW,et at Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.Lancet i: 16–19, 1985.CrossRefGoogle Scholar
  4. 4).
    Ribeiro G, Swindell R: The Christie Hospital Adjuvant Tamoxifen Trial; Status at 10 years.Br J Cancer 57:601–603, 1988.PubMedGoogle Scholar
  5. 5).
    Hubay CA, Pearson OH, Marshall JS,et at Adjuvant therapy of stage II breast cancer; 48 month follow-up of a prospective randomized clinical trial.Breast Cancer Res Treat 1:77–82, 1981.PubMedCrossRefGoogle Scholar
  6. 6).
    Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy.Rev Endo Rel Cancer (October Supplement) :49–55, 1978.Google Scholar
  7. 7).
    Jordan VC, Dix CJ, Allen KE: The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE eds, Adjuvant Therapy of Cancer II, Grune & Stratton Inc, Orlando, ppl9–26, 1979.Google Scholar
  8. 8).
    Jordan VC, Allen KE: Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model.Eur J Cancer 16:239–251, 1980.PubMedGoogle Scholar
  9. 9).
    Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens; Problems and potential for future clinical applications.Breast Cancer Res Treat 3 (suppl):73–86, 1983.CrossRefGoogle Scholar
  10. 10).
    Baum M, Brinkley DM, Dossett JA,et at Improved survival amongst patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.Lancet ii:450, 1983.CrossRefGoogle Scholar
  11. 11).
    Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer; The Scottish Trial; Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.Lancet ii:171–175, 1987.Google Scholar
  12. 12).
    Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.J Natl Cancer Inst 88:1543–1549, 1996.CrossRefGoogle Scholar
  13. 13).
    Osborne CK, Hobbs K, Clark GM: Effects of estrogens and anti-estrogens on growth of human breast cancer cells in athymic nude mice.Cancer Res 45:584–590, 1985.PubMedGoogle Scholar
  14. 14).
    Gottardis MM, Robinson SP, Jordan VC: Estradiolstimulated growth of MCF-7 tumors implanted in athymic mice; A model to study the tumoristatic action of tamoxifen.J Steroid Biochem 20:311–314, 1988.CrossRefGoogle Scholar
  15. 15).
    Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.Cancer Res 48:5183–5187, 1988.PubMedGoogle Scholar
  16. 16).
    Gottardis MM, Wagner RJ, Borden EC,et at Differential ability of antiestrogens to stimulate breast cancer cell line (MCF-7) growthin vivo andin vitro.Cancer Res 49:4765–4769, 1989.PubMedGoogle Scholar
  17. 17).
    Wolf DM, Langan-Fahey SM, Parker CJ,et at Investigation of the mechanism of tamoxifen- stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites.J Natl Cancer Inst 85:806–812, 1993.PubMedCrossRefGoogle Scholar
  18. 18).
    Welshons WV, Jordan VC: Adaptation of estrogendependent MCF-7 cells to low estrogen (phenol red- free) culture.Eur J Cancer Clin Oncol 23:1935–1939, 1987.PubMedCrossRefGoogle Scholar
  19. 19).
    Pink JJ, Jiang S-Y, Fritsch M,et al An estrogenindependent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor- related protein.Cancer Res 55:2583–2590, 1995.PubMedGoogle Scholar
  20. 20).
    Jordan VC: The control of hormone-dependent breast cancer growth; Are we talking about estrogen alone?Eur J Cancer Clin Oncol 24:1245–1248, 1988.PubMedCrossRefGoogle Scholar
  21. 21).
    Wakeling AE: Therapeutic potential of pure antiestrogens in the treatment of breast cancer.J Steroid Biochem Mol Biol 37:771–775, 1990.PubMedCrossRefGoogle Scholar
  22. 22).
    Gottardis MM, Jiang SY, Jeng MH,et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.Cancer Res 49:4090–4093, 1989.PubMedGoogle Scholar
  23. 23).
    Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG,et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human cancer.J Natl Cancer Inst 87:746–750, 1995.PubMedCrossRefGoogle Scholar
  24. 24).
    Howell A, DeFriend D, Robertson H,et al: Response to a specific antiestrogen (ICI 182,780) in tamoxifenresistant breast cancer.Lancet 345:29–30, 1995.PubMedCrossRefGoogle Scholar
  25. 25).
    Howell A, DeFriend DJ, Robertson JF,et al: Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182,780 in women with advanced breast cancer.Br J Cancer 74:300–306, 1996.PubMedGoogle Scholar
  26. 26).
    Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.Cancer Res 44: 4006–4010, 1984.PubMedGoogle Scholar
  27. 27).
    Gottardis MM, Robinson SP, Satyaswaroop PG,et al: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.Cancer Res 48:812–815, 1988.PubMedGoogle Scholar
  28. 28).
    Fornander T, Rutqvist LE, Cedermark B,et al: Adjuvant tamoxifen in early breast cancer; Ocurrence of new primary cancers.Lancet i: 117–120, 1989.CrossRefGoogle Scholar
  29. 29).
    Assikis VJ, Jordan VC: Gynecological effects of tamoxifen and the association with endometrial cancer.Int J Gynaecol Obstet 49:241–257, 1995.PubMedCrossRefGoogle Scholar
  30. 30).
    Assikis VJ, Neven P, Jordan VC,et al: A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.Eur J Cancer 32A: 1464–1476, 1996.CrossRefGoogle Scholar
  31. 31).
    Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen?Eur J Cancer 30A:1714–1721, 1994.CrossRefGoogle Scholar
  32. 32).
    Phillips DH, Carmichael PL, Hewer A,et al: Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products; Comparisons between human, rat and mouse hepatocytes.Carcinogenesis 17:89–94, 1996.PubMedCrossRefGoogle Scholar
  33. 33).
    Martin EA, Rich KJ, White IN,et al: 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen.Carcinogenesis 16:1651–1654, 1995.PubMedCrossRefGoogle Scholar
  34. 34).
    Carmichael PL, Ugwumadu AH, Neven P,et al: Lack of genotoxicity of tamoxifen in human endometrium.Cancer Res 56:1475–1479, 1996.PubMedGoogle Scholar
  35. 35).
    Hemminki K, Rajaniemi H, Lindahl B,et al: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.Cancer Res 56:4374–4377, 1996.PubMedGoogle Scholar
  36. 36).
    International Agency for Research on Cancer (IARC): Tamoxifen.IARC Monogr Eval Carcinog Risks Hum 66:253–365, 1996. (http://www.iarc.fr/preleases/llle.htm)Google Scholar
  37. 37).
    Hayes DF, Van Zyl JA, Hacking A,et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.J Clin Oncol 113:2556–2566, 1995.Google Scholar
  38. 38).
    Vogel CL, Shemano I, Schoenfelder J,et al: Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer.J Clin Oncol 11:345–350, 1993.PubMedGoogle Scholar
  39. 39).
    Stenbygaard LE, Herrstedt J, Thomsen JF,et al Toremifene and tamoxifen in advanced breast cancer; A double-blind cross-over trial.Breast Cancer Res Treat 25:57–63, 1993.PubMedCrossRefGoogle Scholar
  40. 40).
    Merimsky O, Inbar M, Kovner F,et al: Adjuvant tamoxifen; 5 year control of dormant disease.Eur J Cancer 32A:174, 1996.CrossRefGoogle Scholar
  41. 41).
    Ebbs SR, Roberts J, Baum M: Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer; Preliminary communication.J Steroid Biochem 36:239, 1990.PubMedCrossRefGoogle Scholar
  42. 42).
    Hard GC, Iatropoulos MJ, Jordan K,et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.Cancer Res 53:4534–4541, 1993.PubMedGoogle Scholar
  43. 43).
    Jordan VC: Fourteenth Gaddum Memorial Lecture; A current view of tamoxifen for the treatment and prevention of breast cancer.Br J Pharmacol 110:507–517, 1993PubMedGoogle Scholar
  44. 44).
    Jordan VC, Phelps E, Lindgren JU: Effects of antiestrogens on bone in castrated and intact female rats.Breast Cancer Res Treat 10:31–35, 1987.PubMedCrossRefGoogle Scholar
  45. 45).
    Gottardis MM, Jordan VC: Antitumor actions of keoxifene (raloxifene) and tamoxifen in theN-nitrosomethylurea-induced rat mammary carcinoma model.Cancer Res 47:4020–4024, 1987.PubMedGoogle Scholar
  46. 46).
    Gottardis MM, Ricchio ME, Satyaswaroop P,et al: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCalOl) in athymic mice.Cancer Res 50:3189–3192, 1990.PubMedGoogle Scholar
  47. 47).
    Delmas PD, Bjarnason NH, Mitlak BH,et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.N Engl J Med 337:1641–1647, 1997.PubMedCrossRefGoogle Scholar
  48. 48).
    Jordan VC, MacGregor JI, Tonetti DA: Tamoxifen; From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy.Osteoporos Int 7(Sl):S52–57, 1997.PubMedCrossRefGoogle Scholar
  49. 49).
    Jordan VC: Tamoxifen; The herald of a new era of preventive therapeutics.J Natl Cancer Inst 89:747–749, 1997.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1998

Authors and Affiliations

  • Ruth M. O’Regan
    • 1
  • Gale M. England
    • 1
  • Jennifer I. MacGregor
    • 1
  • Kathy A. Yao
    • 1
  • Henry D. Muenzner
    • 1
  • Hiroyuki Takei
    • 1
  • V. Craig Jordan
    • 1
  1. 1.Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations